Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 250

Adverse Effects in AIM-HIGH trial of Niaspan are Consistent With the Results Reported From HPS2-THRIVE Trial of ER Niacin Plus Laropiprant

Posted by fidest press agency su martedì, 26 marzo 2013

Oxford, England, /PRNewswire/ Senior researchers at Oxford University’s Clinical Trial Service Unit welcomed today’s statement by the Principal Investigators of the AIM-HIGH trial about the consistency of the adverse effects seen in the AIM-HIGH trial of extended-release niacin (Niaspan) with those reported from the HPS2-THRIVE trial of extended-release niacin given in combination with laropiprant (Tredaptive). The findings of the HPS2-THRIVE trial of over 25,000 patients with pre-existing cardiovascular disease were presented by the Oxford University scientists at the American College of Cardiology (ACC) meeting in San Francisco on Saturday 9 March 2013. Adding extended-release niacin with laropiprant (which reduces flushing due to niacin) to effective statin-based cholesterol-lowering treatment failed to produce any clear benefits for these high risk patients. In addition, the expected side-effects of niacin were seen: skin rashes, gastro-intestinal (stomach) problems, complications with managing pre-existing diabetes and an increased risk of developing diabetes. Unexpectedly, however, there were also excesses of infections and bleeding (particularly in the gut and brain). The very large randomised HPS2-THRIVE trial was able to show how frequent and how serious these expected and unexpected adverse effects were. On average, about 30 per 1000 patients treated for 4 years with the extended-release niacin/laropiprant combination suffered a serious adverse event – most of which required hospitalisation – due to the study treatment. But, since the HPS2-THRIVE trial tested the combination of extended-release niacin and laropiprant, it is not able to assess directly the separate effects of niacin and of laropiprant.When the Oxford researchers first saw the preliminary results from the HPS2-THRIVE study, they contacted the Principal Investigators of the AIM-HIGH trial which had tested the effects of adding extended-release niacin (Niaspan) alone on top of statin-based treatment. The AIM-HIGH trial involved similar types of patients but it was much smaller, involving 3,400 patients treated for only about 3 years, and it was stopped prematurely in 2011 because of no apparent benefit. In response to the request by the Oxford researchers, the AIM-HIGH investigators looked specifically at all reports of infections and bleeding. They provided analyses of the effects of Niaspan on these outcomes, which they reported to be consistent (albeit based on smaller numbers) with the excesses seen in the HPS2-THRIVE trial. Principal Investigator Jane Armitage said: “The consistency of the AIM-HIGH results on infection and bleeding with the results of HPS2-THRIVE, along with clues from the older literature about the effects of niacin, make us reasonably confident that these are niacin effects. In the light of these findings, we firmly believe that the use of all niacin products used to treat lipids should now be reconsidered.”

7 Risposte to “Adverse Effects in AIM-HIGH trial of Niaspan are Consistent With the Results Reported From HPS2-THRIVE Trial of ER Niacin Plus Laropiprant”

  1. Great weblog right here! Additionally your website loads up fast!
    What web host are you the use of? Can I get your associate link on
    your host? I want my website loaded up as quickly as yours lol

  2. Simply desire to say your article is as astounding. The clearness in your
    post is simply excellent and i can assume you are an expert on this subject.
    Fine with your permission let me to grab your RSS feed to keep updated with forthcoming post.
    Thanks a million and please continue the gratifying work.

  3. Oh my goodness! Awesome article dude! Thank you so much,
    However I am experiencing issues with your RSS. I don’t know why I am unable to join it. Is there anyone else getting the same RSS issues? Anybody who knows the solution can you kindly respond? Thanks!!

  4. Yes! Finally someone writes about entertainment units.

  5. I love Adverse Effects in AIM-HIGH trial of Niaspan are Consistent
    With the Results Reported From HPS2-THRIVE Trial of ER
    Niacin Plus Laropiprant | Fidest – Agenzia giornalistica/press agency
    Thank you for the auspicious writeup. It in truth was a entertainment account it.

    Glance complicated to more added agreeable from
    you! By the way, how could we be in contact?

  6. These three notebook computers are very promising when it comes to efficiency and reliability.
    The ASUS brand is renowned for its good and strong computer
    components and possesses a very good reputation. The case
    from the Medion E5211 looks elegantly simple.

  7. It sold over one million copies and started the jogging craze within the United States.

    It is a stability runners with with Carbon – Span+ for support
    and performance-fast feel. Jonathon Hardcastle writes articles for – In addition, Jonathon also writes articles for and.

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: